|
|
|
| Curative Efficacy of Gemcitabine combined with Nida Platinum in treatment of Patients with Advanced Non-small Cell Lung Cancer and the Effects of Serum Tumor Markers |
| XU Yang, CHEN Dan, LI Fanmin |
| Leshan People's Hospital, Sichuan Leshan 614000, China |
|
|
|
|
Abstract Objective: To study curative efficacy of gemcitabine combined with nida platinum in treatment of patients with advanced non-small cell lung cancer and its effects on the effect of serum tumor markers. Methods: 150 patients of late nonsmall cell lung who received therapy from July 2016 to December 2017 were selected as research objects. 75 cases were randomly divided into observation group and 75 in control group. The observation group was treated with gemcitabine combined with nidaliplatin. The control group was treated with cisplatin. The clinical efficacy and quality of life of the two groups were compared. Two groups of patients were recorded before and after treatment of cancer embryo antigen (CEA), carbohydrate antigen 125 (CA125), cytokeratin fragment antigen 21-1 (CYFRA21-1), and neuron specific enolase (NSE). The adverse reactions of the two groups were recorded. The survival time of the two groups was recorded. Results: After treatment, the effective rate was 54.67%, significantly higher than 33.33% in the control group, and the difference was statistically significant (P<0.05). Before treatment, there was no significant difference in the indexes of the two groups. After treatment, both groups showed a decrease in each index level, which was statistically significant (P<0.05). Observation group CEA, CA125 and cyfra21-1 were both lower than the control group, and the difference was statistically significant (P<0.05). After treatment, there was no significant difference in NSE level between the two groups (P>0.05). After treatment, there was no statistically significant difference between the two groups. The ECOG score of observation group was significantly higher than that in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the difference between the two groups in the survival period, and the observation group was significantly higher than the control group with no progress in survival and median survival, and the difference was statistically significant (P<0.05). The incidence of hair loss, nausea and vomiting in the observation group was significantly lower than that in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the incidence of thrombocytopenia, leukocyte decline, hemoglobin reduction, hepatotoxicity, phlebitis and constipation in both groups (P>0.05). Conclusion: The treatment of patients with advanced non-small cell lung cancer treated by gemcitabine combined with nidaplatin is more effective, with less adverse reactions, and the patient can tolerate the disease, and it is worth promoting the application.
|
|
|
|
|
|
[1] 李艳,郭其森.晚期非小细胞肺癌维持治疗进展[J].中华肿瘤防治杂志,2014,21(10):800~804.
[2] 兰四友,张德芬,邓述恺,等.吉西他滨联合奈达铂治疗晚期非小细胞肺癌的临床观察[J].四川医学,2014,35(6):703~705.
[3] Filosso PL, Guerrera F, Lausi PO et al. Locally advanced non-small cell lung cancer treatment: another step forward[J].Thorac Dis,2017,9(12):4908~4911.
[4] 曾林淼,郑海伦,彭锦芸,等.康莱特联合吉西他滨治疗晚期非小细胞肺癌有效性和安全性的Meta分析[J].中国循证医学杂志,2014,14(07):827~834.
[5] 胡毅,陶海涛.晚期非小细胞肺癌的药物治疗进展[J].中国药物应用与监测,2014,11(6):329~333.
[6] 姚舒洋,钱坤,胡牧,等.吉西他滨联合奈达铂或卡铂一线治疗晚期非小细胞肺癌的疗效及安全性[J].中国医学前沿杂志(电子版),2015,7(2):18~21.
[7] 姚德蛟.康莱特联合吉西他滨、顺铂治疗晚期非小细胞肺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(15):1494~1496.
[8] 鄯慧良.吉西他滨联合奈达铂化疗同步三维适形放疗治疗局部晚期非小细胞肺癌[J].肿瘤基础与临床,2015,28(4):314~316.
[9] Drzewiecka-Jedrzejczyk M, Wlazet R, Terlecka M et al. Serum metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in lung carcinoma patients[J].Thorac Dis,2017,9(12):5306~5313.
[10] Takenaka T. How to manage patients with subcentimeter non-small cell lung cancer[J].Thorac Dis,2017,9(12):4860~4862.
[11] 张晋萍,周丹丽,曹慧,等.晚期非小细胞肺癌患者化疗用药合理性评估[J].中国医院药学杂志,2017,37(13):1309~1314.
[12] 杨桃梅.吉西他滨联合奈达铂治疗晚期肺鳞癌的临床分析[J].肿瘤基础与临床,2016,29(5):413~414. |
|
|
|
2018, Vol. 24 
